GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kilitch Drugs (India) Ltd (NSE:KILITCH) » Definitions » Capex-to-Revenue

Kilitch Drugs (India) (NSE:KILITCH) Capex-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Kilitch Drugs (India) Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Kilitch Drugs (India)'s Capital Expenditure for the three months ended in Dec. 2024 was ₹0.00 Mil. Its Revenue for the three months ended in Dec. 2024 was ₹561.66 Mil.

Hence, Kilitch Drugs (India)'s Capex-to-Revenue for the three months ended in Dec. 2024 was 0.00.


Kilitch Drugs (India) Capex-to-Revenue Historical Data

The historical data trend for Kilitch Drugs (India)'s Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kilitch Drugs (India) Capex-to-Revenue Chart

Kilitch Drugs (India) Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.53 0.07 0.03 0.04

Kilitch Drugs (India) Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kilitch Drugs (India)'s Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Kilitch Drugs (India)'s Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kilitch Drugs (India)'s Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kilitch Drugs (India)'s Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Kilitch Drugs (India)'s Capex-to-Revenue falls into.


;
;

Kilitch Drugs (India) Capex-to-Revenue Calculation

Kilitch Drugs (India)'s Capex-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-64.504) / 1536.062
=0.04

Kilitch Drugs (India)'s Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 561.661
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kilitch Drugs (India)  (NSE:KILITCH) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Kilitch Drugs (India) Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kilitch Drugs (India)'s Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Kilitch Drugs (India) Business Description

Traded in Other Exchanges
Address
Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in the manufacture and sales of pharmaceutical products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, HPURE, and others. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.

Kilitch Drugs (India) Headlines

No Headlines